Acorda's drug treats nerve damage-related ED in preclinical test

Acorda Therapeutics' new neuregulin drug helped treat erectile dysfunction in rats with nerve damage, according to preclinical data the company presented at a recent conference. The ultimate goal would be to use the compound to benefit patients dealing with ED caused by cavernous nerve injury, which can commonly, and inadvertently, result from prostate surgery. Story